Honore Tage

SEC Form 4 insider trading activity

Honore Tage has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Jun 8, 2026.

On the most recent filing, Honore Tage is listed as Director at Vanda Pharmaceuticals Inc. Inside the rolling window, Honore Tage reported no open-market purchases and 1 open-market sale totaling $241K in VNDA.

Companies traded

Other insiders at VNDA

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$241K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
VNDA
Honore Tage
Sale$241KFeb 24SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Honore Tage made?

Honore Tage has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.

Which companies does Honore Tage trade?

Honore Tage has filed SEC Form 4 disclosures for 1 company, including VNDA.

When was Honore Tage's most recent SEC Form 4 filing?

Honore Tage's most recent SEC Form 4 filing on Tracefour is dated Jun 8, 2026.

What is Honore Tage's total buy and sell value in the current window?

Inside the rolling retention window, Honore Tage bought $0 and sold $241K based on SEC Form 4 filings.

What was Honore Tage's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 30,000 VNDA shares on 2026-02-23, worth $241K, per SEC Form 4 filings.